Axiomed Spine Corporation
Early Stage Partners co-led the Series A early stage venture capital investment in the life sciences company Axiomed Spine Corporation, which has developed the Freedom Lumbar disc, a second-generation total disc replacement system to restore native function to people with degenerative disc disease, and has continued to support the company through multiple investment rounds. The company has completed a 50-patient pilot trial in Europe for the Freedom Lumbar Disc, has received a CE mark enabling it to sell products in the EU, and is nearing completion of a pivotal trial in the U.S. in anticipation of FDA clearance. Axiomed also has developed a cervical disc that will soon enter clinical trials in Europe.
Recent Axiomed News
Axiomed Achieves "First in Man" Milestone for Cervical TDR
Axiomed Raises Additional $3.6 Million Series D Capital
Axiomed Expands Series D to $20 Million
Axiomed Freedom® Cervical Disc Receives CE Mark
Axiomed Raises $14.5 Million Series D
Find Out More About ESP
Early Stage Partners co-led the Series A investment in Axiomed Spine Corporation and has continued to support the company through multiple rounds of investment.